Local IGFBP-3 MRNA Expression, Apoptosis and Risk of Colorectal Adenomas

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2008 May 24

PMID 18498652

Citations 15

Authors

Temitope O Keku

Robert S Sandler

James G Simmons

Joseph Galanko

John T Woosley

Michelle Proffitt

Oluwaseun Omofoye

Maya McDoom

Pauline K Lund

Affiliations

Soon will be listed here.

Abstract

Background: IGF binding protein-3 (IGFBP-3) regulates the bioavailability of insulin-like growth factors I and II, and has both anti-proliferative and pro-apoptotic properties. Elevated plasma IGFBP-3 has been associated with reduced risk of colorectal cancer (CRC), but the role of tissue IGFBP-3 is not well defined. We evaluated the association between tissue or plasma IGFBP-3 and risk of colorectal adenomas or low apoptosis.

Methods: Subjects were consenting patients who underwent a clinically indicated colonoscopy at UNC Hospitals and provided information on diet and lifestyle. IGFBP-3 mRNA in normal colon was assessed by real time RT-PCR. Plasma IGFBP-3 was measured by ELISA and apoptosis was determined by morphology on H & E slides. Logistic regression was used to compute odds ratio (OR) and 95% confidence intervals.

Results: We observed a modest correlation between plasma IGFBP-3 and tissue IGFBP-3 expression (p = 0.007). There was no significant association between plasma IGFBP-3 and adenomas or apoptosis. Tissue IGFBP-3 mRNA expression was significantly lower in cases than controls. Subjects in the lowest three quartiles of tissue IGFBP-3 gene expression were more likely to have adenomas. Consistent with previous reports, low apoptosis was significantly associated with increased risk of adenomas (p = 0.003). Surprisingly, local IGFBP-3 mRNA expression was inversely associated with apoptosis.

Conclusion: Low expression of IGFBP-3 mRNA in normal colonic mucosa predicts increased risk of adenomas. Our findings suggest that local IGFBP-3 in the colon may directly increase adenoma risk but IGFBP-3 may act through a pathway other than apoptosis to influence adenoma risk.

Citing Articles

Construction and validation of a novel IGFBP3-related signature to predict prognosis and therapeutic decision making for Hepatocellular Carcinoma.

Chen J, Zhuang W, Xia Y, Yin X, Tu M, Zhang Y PeerJ. 2023; 11:e15554.

PMID: 37397026 PMC: 10312159. DOI: 10.7717/peerj.15554.

Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma.

Ding T, Peng Y, Hong C, Huang B, Liu C, Luo Y Discov Oncol. 2022; 13(1):128.

PMID: 36409444 PMC: 9679126. DOI: 10.1007/s12672-022-00591-1.

Investigation of Insulin-Like Growth Factor-1 (IGF-1), P53, and Wilms' Tumor 1 (WT1) Expression Levels in the Colon Polyp Subtypes in Colon Cancer.

Aslan A, Erdem H, Akcay Celik M, Sahin A, Cankaya S Med Sci Monit. 2019; 25:5510-5517.

PMID: 31341157 PMC: 6676992. DOI: 10.12659/MSM.915335.

Clinical significance of serum IGFBP-3 in colorectal cancer.

Hou Y, Luo P, Ji G, Chen H J Clin Lab Anal. 2019; 33(6):e22912.

PMID: 31218761 PMC: 6642311. DOI: 10.1002/jcla.22912.

Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.

Molnar B, Galamb O, Peterfia B, Wichmann B, Csabai I, Bodor A BMC Cancer. 2018; 18(1):695.

PMID: 29945573 PMC: 6020382. DOI: 10.1186/s12885-018-4609-x.

References

Subar A, Midthune D, Kulldorff M, Brown C, Thompson F, Kipnis V . Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. Am J Epidemiol. 2000; 152(3):279-86. DOI: 10.1093/aje/152.3.279. View

Collard T, Guy M, BUTT A, Perks C, Holly J, Paraskeva C . Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis. 2003; 24(3):393-401. DOI: 10.1093/carcin/24.3.393. View

Lee K, Cohen P . Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. J Endocrinol. 2002; 175(1):33-40. DOI: 10.1677/joe.0.1750033. View

Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H . Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000; 92(19):1592-600. DOI: 10.1093/jnci/92.19.1592. View

Kansra S, Ewton D, Wang J, Friedman E . IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells. Int J Cancer. 2000; 87(3):373-8. DOI: 10.1002/1097-0215(20000801)87:3<373::aid-ijc10>3.0.co;2-x. View

Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E . Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer. 2005; 5:9. PMC: 548269. DOI: 10.1186/1471-2407-5-9. View

Firth S, Baxter R . Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23(6):824-54. DOI: 10.1210/er.2001-0033. View

BUTT A, Firth S, King M, BAXTER R . Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000; 275(50):39174-81. DOI: 10.1074/jbc.M908888199. View

Spoerri P, Caballero S, Wilson S, Shaw L, Grant M . Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Vis Sci. 2002; 44(1):365-9. DOI: 10.1167/iovs.02-0309. View

10.

Hollowood A, Lai T, Perks C, Newcomb P, Alderson D, Holly J . IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer. 2000; 88(3):336-41. View

11.

Winesett D, Ulshen M, Hoyt E, Mohapatra N, Fuller C, Lund P . Regulation and localization of the insulin-like growth factor system in small bowel during altered nutrient status. Am J Physiol. 1995; 268(4 Pt 1):G631-40. DOI: 10.1152/ajpgi.1995.268.4.G631. View

12.

Delellis K, Rinaldi S, Kaaks R, Kolonel L, Henderson B, Le Marchand L . Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2004; 13(9):1444-51. View

13.

Hampel O, Kattan M, Yang G, Haidacher S, Saleh G, Thompson T . Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol. 1998; 159(6):2220-5. DOI: 10.1016/S0022-5347(01)63309-3. View

14.

Serel T, Kecelioglu M . Serum insulin-like growth factor is not a useful marker of prostate cancer. BJU Int. 2000; 85(4):559-60. View

15.

McCaig C, Perks C, Holly J . Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci. 2002; 115(Pt 22):4293-303. DOI: 10.1242/jcs.00097. View

16.

Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C . Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999; 91(7):620-5. DOI: 10.1093/jnci/91.7.620. View

17.

Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N . Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Horm IGF Res. 2000; 10 Suppl A:S30-1. DOI: 10.1016/s1096-6374(00)90014-5. View

18.

Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P . Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998; 279(5350):563-6. DOI: 10.1126/science.279.5350.563. View

19.

Hong J, Zhang G, Dong F, Rechler M . Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem. 2002; 277(12):10489-97. DOI: 10.1074/jbc.M109604200. View

20.

Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E . Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 2002; 50(5):642-6. PMC: 1773192. DOI: 10.1136/gut.50.5.642. View